A couple of months back we discussed that the stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, is best avoided after a negative outcome from its clinical trials for Cabometyx in previously untreated liver cancer patients resulted in a sharp drop in...
A couple of months back we discussed that the stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, is best avoided after a negative outcome from its clinical trials for Cabometyx in previously untreated liver cancer patients resulted in a sharp drop in...
Share this Article
Recommended